Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Change in Lesion Area of Treated Telangiectasia.
研究概览
简要总结
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized by the development of abnormal connections between arteries and veins throughout the body, called vascular malformations. These abnormal blood vessels are referred to as arteriovenous malformations (AVM) if they are large and telangiectasias if they are small. Telangiectasias develop due to irregular growth of blood vessels.
Anti-angiogenic therapy, such as the drug Apo-Timop, curbs the growth of new blood vessels. Apo-Timop is included in a class of medications called beta-blockers. Anti-angiogenic therapies exert their beneficial effects in a number of ways: by disabling the agents that activate and promote cell growth, or by directly blocking the growing blood vessel cells.
The investigators think that anti-angiogenic therapy may lead to the shrinking of telangiectasia in people with HHT. The investigators hope that this study will provide us with proof of this concept and might lead to the development and study of anti-angiogenic therapies to help improve the lives of individuals with vascular malformations.
详细描述
This is a small study of 5 patients from St. Michael's Hospital who have HHT and at least 5 typical telangiectasias.
Patients who anticipate a major surgery during this study or are pregnant, breast feeding or on other beta blocker medication may not enroll in this study.
This study lasts 12 weeks (84 days). During this time, subjects will apply a drop of either Apo-timop 0.5% or a placebo solution to 4 telangiectasias twice daily.
The active study medication is called Apo-Timop and is a clear liquid solution stored in a bottle. An eye dropper is used for application.
- Apo-timop will be applied to 3 telangiectasias and
- a placebo will be applied to one telangiectasia A placebo is an inactive substance, with no active medication in it, and it looks the same as the real medication. There is no potential harm of receiving the placebo. It is necessary to use a placebo to make sure that the effect of Apo-timop can be determined without any bias.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Definite clinical or genetic diagnosis of HHT
- •Known ENG or ALK1 mutation (personal or familial)
- •Age>=18 years
- •At least 5 typical (round/ovoid, not spider or linear) cutaneous telangiectasia (size range 2-5mm) on hands (not including lesions on over inter-phalangeal joints) or face
排除标准
- •Contraindication to systemic beta-blocker (severe asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt heart failure, hypotension, allergy/intolerance/ hypersensitivity to timolol)
- •Current treatment with systemic beta-blocker
- •Current participation in other therapeutic trial for HHT
- •Current pregnancy or breastfeeding.
研究组 & 干预措施
Topical timolol maleate
Drug: • Topical timolol maleate 0.5% drops
- Topical timolol maleate 0.5% drops
- Applied twice daily for 12 weeks (84 days) or until disappearance of lesions
- Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient).
干预措施: Topical timolol maleate (Drug)
Placebo
placebo saline drops
-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient.
干预措施: placebo saline drops (Drug)
结局指标
主要结局
Change in Lesion Area of Treated Telangiectasia.
时间窗: 84 days
Change in lesion area (compared with baseline measurement) of treated telangiectasia.
次要结局
- Serum Angiogenic Markers(84 days)
- Stability of Area of Untreated Telangiectasias Over the 84 Day Period(84 days)
- Descriptive Changes in Histopathology in Baseline vs Treated Lesions(84 days)
- Blood Flow Velocity and Volume Flow Rates(84 days)